EUVIMEDEUVIMED entdecken
Crossref

Pharmacologic Venous Thromboembolism Prophylaxis in Patients with Nontraumatic Subarachnoid Hemorrhage Requiring an External Ventricular Drain

Chidozie Ukpabi iD, Ofer Sadan, Yuyang Shi, Kristy N Greene, Owen Samuels, Subin Mathew, Justin Joy, Yajun Mei, William Asbury

Neurocritical Care · 2024-12 · 41 (3) · 779-787

DOI: 10.1007/s12028-024-01993-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurocritical Care, online erschienen am 10.05.2024. Verfasst von Chidozie Ukpabi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Emory Healthcare, Atlanta, GA, USA. Chidozie.ukpabi@emoryhealthcare.org. Hauptthemen laut MEDLINE: Subarachnoid Hemorrhage, Venous Thromboembolism, Enoxaparin, Anticoagulants. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Optimal pharmacologic thromboprophylaxis dosing is not well described in patients with subarachnoid hemorrhage (SAH) with an external ventricular drain (EVD). Our patients with SAH with an EVD who receive prophylactic enoxaparin are routinely monitored using timed anti-Xa levels. Our primary study goal was to determine the frequency of venous thromboembolism (VTE) and secondary intracranial hemorrhage (ICH) for this population of patients who received pharmacologic prophylaxis with enoxaparin or unfractionated heparin (UFH). METHODS: A retrospective chart review was performed for all patients with SAH admitted to the neurocritical care unit at Emory University Hospital between 2012 and 2017. All patients with SAH who required an EVD were included. RESULTS: Of 1,351 patients screened, 868 required an EVD. Of these 868 patients, 627 received enoxaparin, 114 received UFH, and 127 did not receive pharmacologic prophylaxis. VTE occurred in 7.5% of patients in the enoxaparin group, 4.4% in the UFH group (p = 0.32), and 3.2% in the no VTE prophylaxis group (p = 0.08). Secondary ICH occurred in 3.83% of patients in the enoxaparin group, 3.51% in the UFH group (p = 1), and 3.94% in the no VTE prophylaxis group (p = 0.53). As steady-state anti-Xa levels increased from 0.1 units/mL to > 0.3 units/mL, there was a trend toward a lower incidence of VTE. However, no correlation was noted between rising anti-Xa levels and an increased incidence of secondary ICH. When compared, neither enoxaparin nor UFH use was associated with a significantly reduced incidence of VTE or an increased incidence of ICH. CONCLUSIONS: In this retrospective study of patients with nontraumatic SAH with an EVD who received enoxaparin or UFH VTE prophylaxis or no VTE prophylaxis, there was no statistically significant difference in the incidence of VTE or secondary ICH. For patients receiving prophylactic enoxaparin, achieving higher steady-state target anti-Xa levels may be associated with a lower incidence of VTE without increasing the risk of secondary ICH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Subarachnoid HemorrhageVenous ThromboembolismEnoxaparinAnticoagulantsHeparinHumansFemaleMaleMiddle AgedRetrospective StudiesAgedAdultDrainageIntracranial Hemorrhages

Stichwörter der Autor:innen

Aneurysms/subarachnoid hemorrhageAnticoagulationCerebrospinal fluid drainageCoagulationDeep vein thrombosisEnoxaparinHydrocephalusIntracranial pressureIntraventricular hemorrhageNeurocritical careNeurosurgeryPharmacologyVenous thromboembolism

Substanzen

EnoxaparinAnticoagulantsHeparin

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Emory Healthcare, Atlanta, GA, USA. Chidozie.ukpabi@emoryhealthcare.org.
  • Division of Neurocritical Care, Department of Neurology and Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA.
  • H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
  • Department of Pharmacy, Emory University Hospital Midtown, Atlanta, GA, USA.
  • University of Nebraska Medical Center, Omaha, NE, USA.
  • Department of Clinical Pharmacy, Emory Healthcare, Atlanta, GA, USA.

ORCID-Profile: Chidozie Ukpabi

Zitieren

APA

Ukpabi, C., Sadan, O., Shi, Y., Greene, K. N., Samuels, O., Mathew, S., Joy, J., Mei, Y., & Asbury, W. (2024). Pharmacologic Venous Thromboembolism Prophylaxis in Patients with Nontraumatic Subarachnoid Hemorrhage Requiring an External Ventricular Drain. Neurocritical Care, 41(3), 779-787. https://doi.org/10.1007/s12028-024-01993-5

Vancouver

Ukpabi C, Sadan O, Shi Y, Greene KN, Samuels O, Mathew S, et al. Pharmacologic Venous Thromboembolism Prophylaxis in Patients with Nontraumatic Subarachnoid Hemorrhage Requiring an External Ventricular Drain. Neurocritical Care. 2024;41(3):779-787. doi:10.1007/s12028-024-01993-5

BibTeX
@article{Ukpabi2024,
  author = {Ukpabi, Chidozie and Sadan, Ofer and Shi, Yuyang and Greene, Kristy N and Samuels, Owen and Mathew, Subin and Joy, Justin and Mei, Yajun and Asbury, William},
  title = {Pharmacologic Venous Thromboembolism Prophylaxis in Patients with Nontraumatic Subarachnoid Hemorrhage Requiring an External Ventricular Drain},
  journal = {Neurocritical Care},
  year = {2024},
  volume = {41},
  number = {3},
  pages = {779--787},
  doi = {10.1007/s12028-024-01993-5}
}
Kostenlos starten →